Answers are grounded in this paper and cite their sources.
Rapid development in biopharmaceuticals has put high demands on analytical tools that can provide accurate and comprehensive characterization of protein drugs, including biosimilars. Although the enzyme digestion based "bottom-up" approach is usually the method of choice for this purpose, it only gives peptide-level information and sequence coverage is often incomplete. In this work, we used top-down MS with electron capture dissociation (ECD) to characterize both the primary and higher order structures of a therapeutic protein interferon and its variants. Accurate mass measurement at the intact protein level combined with top-down ECD fragmentation enabled unambiguous protein sequence confirmation and identification of all PTMs. Combining hydrogen/deuterium exchange and rapid disulfide reduction with top-down ECD on the LC time scale, we have investigated the differences in higher order structure between the protein variants, as well as the impact of PTMs on protein conformation.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: